214 related articles for article (PubMed ID: 23762498)
1. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
[TBL] [Abstract][Full Text] [Related]
2. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
3. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
4. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
[TBL] [Abstract][Full Text] [Related]
5. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.
Zemp FJ; McKenzie BA; Lun X; Maxwell L; Reilly KM; McFadden G; Yong VW; Forsyth PA
PLoS One; 2013; 8(6):e65801. PubMed ID: 23762429
[TBL] [Abstract][Full Text] [Related]
6. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA
Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023
[TBL] [Abstract][Full Text] [Related]
7. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
8. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.
Pisklakova A; McKenzie B; Zemp F; Lun X; Kenchappa RS; Etame AB; Rahman MM; Reilly K; Pilon-Thomas S; McFadden G; Kurz E; Forsyth PA
Neuro Oncol; 2016 Aug; 18(8):1088-1098. PubMed ID: 26962017
[TBL] [Abstract][Full Text] [Related]
9. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
[TBL] [Abstract][Full Text] [Related]
10. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.
Weng M; Gong W; Ma M; Chu B; Qin Y; Zhang M; Lun X; McFadden G; Forsyth P; Yang Y; Quan Z
Mol Cancer; 2014 Apr; 13():82. PubMed ID: 24725816
[TBL] [Abstract][Full Text] [Related]
11. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.
Correa RJ; Komar M; Tong JG; Sivapragasam M; Rahman MM; McFadden G; Dimattia GE; Shepherd TG
Gynecol Oncol; 2012 May; 125(2):441-50. PubMed ID: 22306204
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
[TBL] [Abstract][Full Text] [Related]
14. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.
Barrett JW; Alston LR; Wang F; Stanford MM; Gilbert PA; Gao X; Jimenez J; Villeneuve D; Forsyth P; McFadden G
J Neurovirol; 2007 Dec; 13(6):549-60. PubMed ID: 18097886
[TBL] [Abstract][Full Text] [Related]
15. Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.
Irwin CR; Favis NA; Agopsowicz KC; Hitt MM; Evans DH
PLoS One; 2013; 8(12):e84134. PubMed ID: 24391902
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines.
Zhang QS; Zhang M; Huang XJ; Liu XJ; Li WP
Exp Ther Med; 2017 Jul; 14(1):344-348. PubMed ID: 28672936
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
18. Proteomic comparison of 3D and 2D glioma models reveals increased HLA-E expression in 3D models is associated with resistance to NK cell-mediated cytotoxicity.
He W; Kuang Y; Xing X; Simpson RJ; Huang H; Yang T; Chen J; Yang L; Liu E; He W; Gu J
J Proteome Res; 2014 May; 13(5):2272-81. PubMed ID: 24742303
[TBL] [Abstract][Full Text] [Related]
19. Experimental appraisal of the lack of antitumor natural killer cell-mediated immunosurveillance in response to lymphomas growing in the mouse brain.
Yamasaki T; Moritake K; Klein G
J Neurosurg; 2003 Mar; 98(3):599-606. PubMed ID: 12650434
[TBL] [Abstract][Full Text] [Related]
20. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
